Global Tourette Syndrome Treatment Market
Global Tourette Syndrome Treatment Market

Tourette Syndrome Treatment Comprehensive Study by Treatment (Medication, Therapy), Distribution Channel (Online, Offline), Medication (Botulinum (Botox) injections, ADHD medications, Central adrenergic inhibitors, Antidepressants, Antiseizure medications), Tics type (Motor Tics (Simple tics, Complex tics), Vocal Tics (Simple tics, Complex tics), Others), End User (Infants, Older teenage, Adult patients) Players and Region - Global Market Outlook to 2026

Tourette Syndrome Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jan 2021 Edition 217 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Tourette Syndrome Treatment Market?

In the course of recent many years, the A determination of Tourette disorder may be disregarded in light of the fact that the signs can impersonate different conditions. Eye flickering may be at first connected with vision issues, or wheezing ascribed to hypersensitivities, as indicated by the exploration Tourette disorder treatment happens in 6 cases for every 1,000 kids, signification roughly 300,000 kids have the condition in the United States. Tourette condition is an uncommon and serious neurological problem that causes spasms. Spasm is a redundant compulsory development, unexpected, no cadenced engine developments. Moreover, it is identified with neurobehavioral issues like impulsivity, issues with perusing and composing, over the top urgent side effects. It very well may be treated with neuroleptics; haloperidol and pimozide are to a great extent utilized medications for Tourette disorder. Different drugs, for example, guanfacine and clonidine are helpful to treat the seriousness of spasms. There are four sorts of spasms engine spasms (uncontrolled body developments), vocal spasms (upheaval of sound), straightforward spasms (incorporates not many pieces of the body), and complex spasms (contains a few pieces of the body).

The market study is being classified and major geographies with country level break-up.

Neurocrine Biosciences, Inc. (United States), Novartis AG (Switzerland), Otsuka Pharmaceutical Co., Ltd. (Japan), Teva Pharmaceuticals USA, Inc. (Israel), Apotex, Inc. (Canada), Janssen Pharmaceuticals, Inc. (Belgium), Zydus Pharmaceuticals USA, Inc. (India), Eli Lilly (United States) and Torrent Pharmaceuticals Limited. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Boehringer Ingelheim (Germany) and Sandoz (Germany).

The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Tourette Syndrome Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Tourette Syndrome Treatment market by Type, Application and Region.

On the basis of geography, the market of Tourette Syndrome Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • The increasing number of disorders Treatment of tics in people with Tourette syndrome and chronic tic disorders
  • Increasing chronic tic disorders globally

Market Trend
  • Increased several investigations and research and development activity made for the treatment of Tourette syndrome

Restraints
  • There is a lower prevalence for a diagnosis

Opportunities
  • Drug approvals by regulatory authorities are expected to boost the global Tourette syndrome treatment market growth.

Challenges
  • Lack of availability of the exact solution for the Tourette Syndrome Treatment


In March 2019 Lundbeck Denmark-based company pharmaceutical company Lundbeck leaps into Tourette’s pipeline By taking out Abide Therapeutics. Abide Therapeutics for an initial USD 250m. The California biotech has developed a specialism in serine hydrolase biology and generated a lead project in Tourette’s syndrome, a neurological disorder that sits squarely in Lundbeck’s CNS-focused wheelhouse.


Analyst Comment
The American Academy of Neurology is the world's greatest relationship of nervous system specialists framework trained professionals and neuroscience specialists, with 36,000 people. The AAN is committed to propelling the best patient-centered neurologic thought. A sensory system expert is an expert with specific arrangement in diagnosing, treating, and supervising issues of the cerebrum and tangible framework, for instance, Alzheimer's disease, stroke, migraine, distinctive sclerosis, power outage, Parkinson's disorder, and epilepsy

Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Tourette Syndrome Treatment Provider, Government Regulatory and Research Organizations and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Treatment
  • Medication
  • Therapy

By Distribution Channel
  • Online
  • Offline

By Medication
  • Botulinum (Botox) injections
  • ADHD medications
  • Central adrenergic inhibitors
  • Antidepressants
  • Antiseizure medications

By Tics type
  • Motor Tics (Simple tics, Complex tics)
  • Vocal Tics (Simple tics, Complex tics)
  • Others

By End User
  • Infants
  • Older teenage
  • Adult patients

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing number of disorders Treatment of tics in people with Tourette syndrome and chronic tic disorders
      • 3.2.2. Increasing chronic tic disorders globally
    • 3.3. Market Challenges
      • 3.3.1. Lack of availability of the exact solution for the Tourette Syndrome Treatment
    • 3.4. Market Trends
      • 3.4.1. Increased several investigations and research and development activity made for the treatment of Tourette syndrome
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tourette Syndrome Treatment, by Treatment, Distribution Channel, Medication, Tics type, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Tourette Syndrome Treatment (Value)
      • 5.2.1. Global Tourette Syndrome Treatment by: Treatment (Value)
        • 5.2.1.1. Medication
        • 5.2.1.2. Therapy
      • 5.2.2. Global Tourette Syndrome Treatment by: Distribution Channel (Value)
        • 5.2.2.1. Online
        • 5.2.2.2. Offline
      • 5.2.3. Global Tourette Syndrome Treatment by: Medication (Value)
        • 5.2.3.1. Botulinum (Botox) injections
        • 5.2.3.2. ADHD medications
        • 5.2.3.3. Central adrenergic inhibitors
        • 5.2.3.4. Antidepressants
        • 5.2.3.5. Antiseizure medications
      • 5.2.4. Global Tourette Syndrome Treatment by: Tics type (Value)
        • 5.2.4.1. Motor Tics (Simple tics, Complex tics)
        • 5.2.4.2. Vocal Tics (Simple tics, Complex tics)
        • 5.2.4.3. Others
      • 5.2.5. Global Tourette Syndrome Treatment by: End User (Value)
        • 5.2.5.1. Infants
        • 5.2.5.2. Older teenage
        • 5.2.5.3. Adult patients
      • 5.2.6. Global Tourette Syndrome Treatment Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Tourette Syndrome Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Neurocrine Biosciences, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Teva Pharmaceuticals USA, Inc. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apotex, Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Janssen Pharmaceuticals, Inc. (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zydus Pharmaceuticals USA, Inc. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Torrent Pharmaceuticals Limited. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Tourette Syndrome Treatment Sale, by Treatment, Distribution Channel, Medication, Tics type, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Tourette Syndrome Treatment (Value)
      • 7.2.1. Global Tourette Syndrome Treatment by: Treatment (Value)
        • 7.2.1.1. Medication
        • 7.2.1.2. Therapy
      • 7.2.2. Global Tourette Syndrome Treatment by: Distribution Channel (Value)
        • 7.2.2.1. Online
        • 7.2.2.2. Offline
      • 7.2.3. Global Tourette Syndrome Treatment by: Medication (Value)
        • 7.2.3.1. Botulinum (Botox) injections
        • 7.2.3.2. ADHD medications
        • 7.2.3.3. Central adrenergic inhibitors
        • 7.2.3.4. Antidepressants
        • 7.2.3.5. Antiseizure medications
      • 7.2.4. Global Tourette Syndrome Treatment by: Tics type (Value)
        • 7.2.4.1. Motor Tics (Simple tics, Complex tics)
        • 7.2.4.2. Vocal Tics (Simple tics, Complex tics)
        • 7.2.4.3. Others
      • 7.2.5. Global Tourette Syndrome Treatment by: End User (Value)
        • 7.2.5.1. Infants
        • 7.2.5.2. Older teenage
        • 7.2.5.3. Adult patients
      • 7.2.6. Global Tourette Syndrome Treatment Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tourette Syndrome Treatment: by Treatment(USD Million)
  • Table 2. Tourette Syndrome Treatment Medication , by Region USD Million (2015-2020)
  • Table 3. Tourette Syndrome Treatment Therapy , by Region USD Million (2015-2020)
  • Table 4. Tourette Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 5. Tourette Syndrome Treatment Online , by Region USD Million (2015-2020)
  • Table 6. Tourette Syndrome Treatment Offline , by Region USD Million (2015-2020)
  • Table 7. Tourette Syndrome Treatment: by Medication(USD Million)
  • Table 8. Tourette Syndrome Treatment Botulinum (Botox) injections , by Region USD Million (2015-2020)
  • Table 9. Tourette Syndrome Treatment ADHD medications , by Region USD Million (2015-2020)
  • Table 10. Tourette Syndrome Treatment Central adrenergic inhibitors , by Region USD Million (2015-2020)
  • Table 11. Tourette Syndrome Treatment Antidepressants , by Region USD Million (2015-2020)
  • Table 12. Tourette Syndrome Treatment Antiseizure medications , by Region USD Million (2015-2020)
  • Table 13. Tourette Syndrome Treatment: by Tics type(USD Million)
  • Table 14. Tourette Syndrome Treatment Motor Tics (Simple tics, Complex tics) , by Region USD Million (2015-2020)
  • Table 15. Tourette Syndrome Treatment Vocal Tics (Simple tics, Complex tics) , by Region USD Million (2015-2020)
  • Table 16. Tourette Syndrome Treatment Others , by Region USD Million (2015-2020)
  • Table 17. Tourette Syndrome Treatment: by End User(USD Million)
  • Table 18. Tourette Syndrome Treatment Infants , by Region USD Million (2015-2020)
  • Table 19. Tourette Syndrome Treatment Older teenage , by Region USD Million (2015-2020)
  • Table 20. Tourette Syndrome Treatment Adult patients , by Region USD Million (2015-2020)
  • Table 21. South America Tourette Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 23. South America Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 24. South America Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 25. South America Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 26. South America Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 27. Brazil Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 28. Brazil Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 29. Brazil Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 30. Brazil Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 31. Brazil Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 32. Argentina Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 33. Argentina Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 34. Argentina Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 35. Argentina Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 36. Argentina Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 37. Rest of South America Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 38. Rest of South America Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 39. Rest of South America Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 40. Rest of South America Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 41. Rest of South America Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 42. Asia Pacific Tourette Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 43. Asia Pacific Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 44. Asia Pacific Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 45. Asia Pacific Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 46. Asia Pacific Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 47. Asia Pacific Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 48. China Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 49. China Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 50. China Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 51. China Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 52. China Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 53. Japan Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 54. Japan Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 55. Japan Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 56. Japan Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 57. Japan Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 58. India Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 59. India Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 60. India Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 61. India Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 62. India Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 63. South Korea Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 64. South Korea Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 65. South Korea Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 66. South Korea Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 67. South Korea Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 68. Taiwan Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 69. Taiwan Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 70. Taiwan Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 71. Taiwan Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 72. Taiwan Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 73. Australia Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 74. Australia Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 75. Australia Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 76. Australia Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 77. Australia Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 78. Rest of Asia-Pacific Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 79. Rest of Asia-Pacific Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 80. Rest of Asia-Pacific Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 83. Europe Tourette Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 84. Europe Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 85. Europe Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 86. Europe Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 87. Europe Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 88. Europe Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 89. Germany Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 90. Germany Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 91. Germany Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 92. Germany Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 93. Germany Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 94. France Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 95. France Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 96. France Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 97. France Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 98. France Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 99. Italy Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 100. Italy Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 101. Italy Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 102. Italy Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 103. Italy Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 104. United Kingdom Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 105. United Kingdom Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 106. United Kingdom Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 107. United Kingdom Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 108. United Kingdom Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 109. Netherlands Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 110. Netherlands Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 111. Netherlands Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 112. Netherlands Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 113. Netherlands Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 114. Rest of Europe Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 115. Rest of Europe Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 116. Rest of Europe Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 117. Rest of Europe Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 118. Rest of Europe Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 119. MEA Tourette Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 120. MEA Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 121. MEA Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 122. MEA Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 123. MEA Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 124. MEA Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 125. Middle East Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 126. Middle East Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 127. Middle East Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 128. Middle East Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 129. Middle East Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 130. Africa Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 131. Africa Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 132. Africa Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 133. Africa Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 134. Africa Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 135. North America Tourette Syndrome Treatment, by Country USD Million (2015-2020)
  • Table 136. North America Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 137. North America Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 138. North America Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 139. North America Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 140. North America Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 141. United States Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 142. United States Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 143. United States Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 144. United States Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 145. United States Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 146. Canada Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 147. Canada Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 148. Canada Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 149. Canada Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 150. Canada Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 151. Mexico Tourette Syndrome Treatment, by Treatment USD Million (2015-2020)
  • Table 152. Mexico Tourette Syndrome Treatment, by Distribution Channel USD Million (2015-2020)
  • Table 153. Mexico Tourette Syndrome Treatment, by Medication USD Million (2015-2020)
  • Table 154. Mexico Tourette Syndrome Treatment, by Tics type USD Million (2015-2020)
  • Table 155. Mexico Tourette Syndrome Treatment, by End User USD Million (2015-2020)
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Company Basic Information, Sales Area and Its Competitors
  • Table 163. Company Basic Information, Sales Area and Its Competitors
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Tourette Syndrome Treatment: by Treatment(USD Million)
  • Table 166. Tourette Syndrome Treatment Medication , by Region USD Million (2021-2026)
  • Table 167. Tourette Syndrome Treatment Therapy , by Region USD Million (2021-2026)
  • Table 168. Tourette Syndrome Treatment: by Distribution Channel(USD Million)
  • Table 169. Tourette Syndrome Treatment Online , by Region USD Million (2021-2026)
  • Table 170. Tourette Syndrome Treatment Offline , by Region USD Million (2021-2026)
  • Table 171. Tourette Syndrome Treatment: by Medication(USD Million)
  • Table 172. Tourette Syndrome Treatment Botulinum (Botox) injections , by Region USD Million (2021-2026)
  • Table 173. Tourette Syndrome Treatment ADHD medications , by Region USD Million (2021-2026)
  • Table 174. Tourette Syndrome Treatment Central adrenergic inhibitors , by Region USD Million (2021-2026)
  • Table 175. Tourette Syndrome Treatment Antidepressants , by Region USD Million (2021-2026)
  • Table 176. Tourette Syndrome Treatment Antiseizure medications , by Region USD Million (2021-2026)
  • Table 177. Tourette Syndrome Treatment: by Tics type(USD Million)
  • Table 178. Tourette Syndrome Treatment Motor Tics (Simple tics, Complex tics) , by Region USD Million (2021-2026)
  • Table 179. Tourette Syndrome Treatment Vocal Tics (Simple tics, Complex tics) , by Region USD Million (2021-2026)
  • Table 180. Tourette Syndrome Treatment Others , by Region USD Million (2021-2026)
  • Table 181. Tourette Syndrome Treatment: by End User(USD Million)
  • Table 182. Tourette Syndrome Treatment Infants , by Region USD Million (2021-2026)
  • Table 183. Tourette Syndrome Treatment Older teenage , by Region USD Million (2021-2026)
  • Table 184. Tourette Syndrome Treatment Adult patients , by Region USD Million (2021-2026)
  • Table 185. South America Tourette Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 186. South America Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 187. South America Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 188. South America Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 189. South America Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 190. South America Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 191. Brazil Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 192. Brazil Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 193. Brazil Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 194. Brazil Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 195. Brazil Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 196. Argentina Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 197. Argentina Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 198. Argentina Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 199. Argentina Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 200. Argentina Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 201. Rest of South America Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 202. Rest of South America Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 203. Rest of South America Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 204. Rest of South America Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 205. Rest of South America Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 206. Asia Pacific Tourette Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 207. Asia Pacific Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 208. Asia Pacific Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 209. Asia Pacific Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 210. Asia Pacific Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 211. Asia Pacific Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 212. China Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 213. China Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 214. China Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 215. China Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 216. China Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 217. Japan Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 218. Japan Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 219. Japan Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 220. Japan Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 221. Japan Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 222. India Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 223. India Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 224. India Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 225. India Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 226. India Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 227. South Korea Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 228. South Korea Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 229. South Korea Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 230. South Korea Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 231. South Korea Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 232. Taiwan Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 233. Taiwan Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 234. Taiwan Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 235. Taiwan Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 236. Taiwan Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 237. Australia Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 238. Australia Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 239. Australia Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 240. Australia Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 241. Australia Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 242. Rest of Asia-Pacific Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 243. Rest of Asia-Pacific Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 244. Rest of Asia-Pacific Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 245. Rest of Asia-Pacific Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 246. Rest of Asia-Pacific Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 247. Europe Tourette Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 248. Europe Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 249. Europe Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 250. Europe Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 251. Europe Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 252. Europe Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 253. Germany Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 254. Germany Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 255. Germany Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 256. Germany Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 257. Germany Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 258. France Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 259. France Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 260. France Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 261. France Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 262. France Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 263. Italy Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 264. Italy Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 265. Italy Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 266. Italy Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 267. Italy Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 268. United Kingdom Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 269. United Kingdom Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 270. United Kingdom Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 271. United Kingdom Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 272. United Kingdom Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 273. Netherlands Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 274. Netherlands Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 275. Netherlands Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 276. Netherlands Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 277. Netherlands Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 278. Rest of Europe Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 279. Rest of Europe Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 280. Rest of Europe Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 281. Rest of Europe Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 282. Rest of Europe Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 283. MEA Tourette Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 284. MEA Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 285. MEA Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 286. MEA Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 287. MEA Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 288. MEA Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 289. Middle East Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 290. Middle East Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 291. Middle East Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 292. Middle East Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 293. Middle East Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 294. Africa Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 295. Africa Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 296. Africa Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 297. Africa Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 298. Africa Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 299. North America Tourette Syndrome Treatment, by Country USD Million (2021-2026)
  • Table 300. North America Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 301. North America Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 302. North America Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 303. North America Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 304. North America Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 305. United States Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 306. United States Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 307. United States Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 308. United States Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 309. United States Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 310. Canada Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 311. Canada Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 312. Canada Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 313. Canada Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 314. Canada Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 315. Mexico Tourette Syndrome Treatment, by Treatment USD Million (2021-2026)
  • Table 316. Mexico Tourette Syndrome Treatment, by Distribution Channel USD Million (2021-2026)
  • Table 317. Mexico Tourette Syndrome Treatment, by Medication USD Million (2021-2026)
  • Table 318. Mexico Tourette Syndrome Treatment, by Tics type USD Million (2021-2026)
  • Table 319. Mexico Tourette Syndrome Treatment, by End User USD Million (2021-2026)
  • Table 320. Research Programs/Design for This Report
  • Table 321. Key Data Information from Secondary Sources
  • Table 322. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tourette Syndrome Treatment: by Treatment USD Million (2015-2020)
  • Figure 5. Global Tourette Syndrome Treatment: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Tourette Syndrome Treatment: by Medication USD Million (2015-2020)
  • Figure 7. Global Tourette Syndrome Treatment: by Tics type USD Million (2015-2020)
  • Figure 8. Global Tourette Syndrome Treatment: by End User USD Million (2015-2020)
  • Figure 9. South America Tourette Syndrome Treatment Share (%), by Country
  • Figure 10. Asia Pacific Tourette Syndrome Treatment Share (%), by Country
  • Figure 11. Europe Tourette Syndrome Treatment Share (%), by Country
  • Figure 12. MEA Tourette Syndrome Treatment Share (%), by Country
  • Figure 13. North America Tourette Syndrome Treatment Share (%), by Country
  • Figure 14. Global Tourette Syndrome Treatment share by Players 2020 (%)
  • Figure 15. Global Tourette Syndrome Treatment share by Players (Top 3) 2020(%)
  • Figure 16. Global Tourette Syndrome Treatment share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Neurocrine Biosciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Neurocrine Biosciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 20. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 22. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 24. Teva Pharmaceuticals USA, Inc. (Israel) Revenue, Net Income and Gross profit
  • Figure 25. Teva Pharmaceuticals USA, Inc. (Israel) Revenue: by Geography 2020
  • Figure 26. Apotex, Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 27. Apotex, Inc. (Canada) Revenue: by Geography 2020
  • Figure 28. Janssen Pharmaceuticals, Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 29. Janssen Pharmaceuticals, Inc. (Belgium) Revenue: by Geography 2020
  • Figure 30. Zydus Pharmaceuticals USA, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 31. Zydus Pharmaceuticals USA, Inc. (India) Revenue: by Geography 2020
  • Figure 32. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly (United States) Revenue: by Geography 2020
  • Figure 34. Torrent Pharmaceuticals Limited. (United States) Revenue, Net Income and Gross profit
  • Figure 35. Torrent Pharmaceuticals Limited. (United States) Revenue: by Geography 2020
  • Figure 36. Global Tourette Syndrome Treatment: by Treatment USD Million (2021-2026)
  • Figure 37. Global Tourette Syndrome Treatment: by Distribution Channel USD Million (2021-2026)
  • Figure 38. Global Tourette Syndrome Treatment: by Medication USD Million (2021-2026)
  • Figure 39. Global Tourette Syndrome Treatment: by Tics type USD Million (2021-2026)
  • Figure 40. Global Tourette Syndrome Treatment: by End User USD Million (2021-2026)
  • Figure 41. South America Tourette Syndrome Treatment Share (%), by Country
  • Figure 42. Asia Pacific Tourette Syndrome Treatment Share (%), by Country
  • Figure 43. Europe Tourette Syndrome Treatment Share (%), by Country
  • Figure 44. MEA Tourette Syndrome Treatment Share (%), by Country
  • Figure 45. North America Tourette Syndrome Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Neurocrine Biosciences, Inc. (United States)
  • Novartis AG (Switzerland)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Teva Pharmaceuticals USA, Inc. (Israel)
  • Apotex, Inc. (Canada)
  • Janssen Pharmaceuticals, Inc. (Belgium)
  • Zydus Pharmaceuticals USA, Inc. (India)
  • Eli Lilly (United States)
  • Torrent Pharmaceuticals Limited. (United States)
Additional players considered in the study are as follows:
Boehringer Ingelheim (Germany) , Sandoz (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation